247 related articles for article (PubMed ID: 22859719)
1. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
2. Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling.
Hall B; Nakashima H; Sun ZJ; Sato Y; Bian Y; Husain SR; Puri RK; Kulkarni AB
J Transl Med; 2013 Feb; 11():45. PubMed ID: 23421960
[TBL] [Abstract][Full Text] [Related]
3. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
4. Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation.
Bian Y; Hall B; Sun ZJ; Molinolo A; Chen W; Gutkind JS; Waes CV; Kulkarni AB
Oncogene; 2012 Jul; 31(28):3322-32. PubMed ID: 22037217
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model.
Sun ZJ; Zhang L; Zhang W; Hall B; Bian Y; Kulkarni AB
PLoS One; 2013; 8(10):e74888. PubMed ID: 24124460
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
[TBL] [Abstract][Full Text] [Related]
7. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
8. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Ma SR; Wang WM; Huang CF; Zhang WF; Sun ZJ
Oncotarget; 2015 Apr; 6(11):8807-21. PubMed ID: 25871396
[TBL] [Abstract][Full Text] [Related]
9. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
10. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway.
Bian Y; Terse A; Du J; Hall B; Molinolo A; Zhang P; Chen W; Flanders KC; Gutkind JS; Wakefield LM; Kulkarni AB
Cancer Res; 2009 Jul; 69(14):5918-26. PubMed ID: 19584284
[TBL] [Abstract][Full Text] [Related]
11. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model.
Raimondi AR; Molinolo A; Gutkind JS
Cancer Res; 2009 May; 69(10):4159-66. PubMed ID: 19435901
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
15. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
16. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.
Czerninski R; Amornphimoltham P; Patel V; Molinolo AA; Gutkind JS
Cancer Prev Res (Phila); 2009 Jan; 2(1):27-36. PubMed ID: 19139015
[TBL] [Abstract][Full Text] [Related]
17. Inducible TgfbR1 and Pten deletion in a model of tongue carcinogenesis and chemoprevention.
Lamenza FF; Ryan NM; Upadhaya P; Siddiqui A; Jordanides PP; Springer A; Roth P; Pracha H; Iwenofu OH; Oghumu S
Cancer Gene Ther; 2023 Aug; 30(8):1167-1177. PubMed ID: 37231058
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
[TBL] [Abstract][Full Text] [Related]
19. PTEN deficiency contributes to the development and progression of head and neck cancer.
Squarize CH; Castilho RM; Abrahao AC; Molinolo A; Lingen MW; Gutkind JS
Neoplasia; 2013 May; 15(5):461-71. PubMed ID: 23633918
[TBL] [Abstract][Full Text] [Related]
20. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
